Translocator protein facilitates neutrophil-mediated mucosal inflammation in inflammatory bowel diseases

Figure 5 Translocator protein expression is significantly upregulated in mice with colitis, n = 6 in each group. A: The body weight of mice receiving H₂O or dextran sodium sulfate (DSS) is monitored weekly. Changes in body weight are expressed as a percentage of the original weight at the beginning of the experiments. ^aP < 0.05, ^bP < 0.01 vs mice those received H₂O at the end of the 8^th week; B: Changes in disease activity index score between the two groups during the experiment; C: Gross morphology of the large bowels at the end of the 8^th week after receiving DSS; D: Colon length is measured and recorded. ^bP < 0.01 vs mice those received H₂O; E: Histological appearance of colonic sections after hematoxylin and eosin. Original magnification 200 ×; F: Pathological scores of colonic sections are shown in the chart; G: Representative immunofluorescent images of the colonic mucosa for staining with 4'-6-diamidino-2-phenylindole (blue), anti-TSPO (red), and anti-myeloperoxidase (MPO) (green). The white arrows indicate representative TSPO⁺ MPO⁺ cells. Original magnification 400 ×; H: Representative [¹⁸F] labeled N,N-diethyl-2-(2-[4-(2-fluoroethoxy)phenyl]-5,7-dimethylpyrazolo[1,5-alpha]pyrimidine-3-yl)acetamide (DPA-714) uptake according to micro-positron emission tomography-computed tomography imaging in wild-type (WT) mice with H₂O and those with DSS treatment. Colon [¹⁸F]DPA-714 uptake is higher in the WT mice with DSS treatment than in those with H₂O treatment. Regions of interest drawn in the colon tissue are showed as white arrows on each image. n: The biologically independent replicates used in the statistical analyses. DSS: Dextran sodium sulfate; TSPO: Translocator protein; MPO: Myeloperoxidase; DAPI: 4'-6-diamidino-2-phenylindole.